Contact Us
Drug Search Results
More Filters [+]

E-8001

Alternative Names: e-8001, e 8001, e8001
Latest Update: 2023-09-27
Latest Update Note: PubMed Publication

Product Description

E-8001 is an intravenously administered drug candidate from Eisai. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04609852?term=E-8001&draw=2&rank=1)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for E-8001

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
E8001-J081-001

P1

Completed

Healthy Volunteers

2023-08-18

28%

Recent News Events

Date

Type

Title

09/27/2023

PubMed

 Delayed nasoseptal flap reuse in patients with revision endoscopic endonasal anterior skull base surgery.

05/07/2020

PubMed

 Rapidly Developing Methicillin-Resistant Staphylococcus Aureus Pericarditis and Pericardial Tamponade.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions